.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,849,752

« Back to Dashboard
Patent 5,849,752 protects AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER and AVELOX and is included in two NDAs. There has been one Paragraph IV challenge on Avelox in Sodium Chloride 0.8% in plastic container. There are three tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has forty-nine patent family members in thirty-nine countries.

Summary for Patent: 5,849,752

Title: Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification
Abstract:The invention relates to the new monohydrate of 1-cyclopropyl-7-([S,S]-2,8-diazabicyclo-[4.3.0]non-8-yl)6-fluoro-1,4-dihyd ro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride (CDCH), a process for its preparation and pharmaceutical formulations which comprise this monohydrate as the active compound.
Inventor(s): Grunenberg; Alfons (Dormagen, DE), Bosche; Patrick (Odenthal, DE)
Assignee: Bayer Aktiengesellschaft (Leverkusen, DE)
Application Number:08/760,543
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 8th percentile
Forward Citations: 4th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bayer Hlthcare
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER
moxifloxacin hydrochloride
SOLUTION;IV (INFUSION)021277-001Nov 30, 2001RXYes5,849,752► subscribe METHOD OF COMBATING BACTERIA IN A PATIENT
Bayer Hlthcare
AVELOX
moxifloxacin hydrochloride
TABLET;ORAL021085-001Dec 10, 1999RXYes5,849,752► subscribe METHOD OF COMBATING BACTERIA IN A PATIENT
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,849,752

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany195 46 249.1Dec 12, 1995

International Patent Family for Patent: 5,849,752

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina005009► subscribe
Austria221531► subscribe
Australia708006► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc